Beat Childhood Cancer Specimen Banking and Data Registry
This study is creating a registry of information and banked samples from children, adolescents, and young adults with cancer or who are cancer survivors. There is no intervention or treatment being tested; it's an observational study. Researchers want to understand the connection between changes in genes (genomic alterations) and how cancer progresses. They hope to identify different types of gene changes within tumors and see how many of these changes could lead to new treatment options. The study aims to collect this information over 10 years. You can join if you have suspected or confirmed childhood cancer, are a survivor (more than 6 months off treatment), or have a related condition. The current recruitment status is unclear.
- Study design
- This is an observational study with a planned enrollment of 1000 participants. It is designed to collect data and specimens without any specific treatment.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goals of the study are measured at 10 years, indicating a long-term follow-up period for data collection.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Beat Childhood Cancer Specimen Banking and Data Registry
At a glance
Conditions
Where it's being run
18 sites across 14 statesStudy leadership
- Giselle Sholler, MD · STUDY_CHAIR · Beat Childhood Cancer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Create a data registry of clinical and molecular/genomic data10 Years
Create a data registry of clinical and molecular/genomic data from cancer patients who have undergone biopsy or surgical resection for clinical care to better understand the relationship between genomic and molecular information and clinical outcomes.
- Determine number and types of genomic alterations within tumor types/subtypes10 Years
Define genomic landscape of pediatric cancers through the determination of the number and types of genomic alterations within tumor types/subtypes, across tumor types, and tumor evolution over time.
- Evaluate the rate of actionable genomic alternations10 Years
Evaluate the rate of actionable genomic alternations resulting in associated targeted therapies relative to all actionable genomic alterations.
- Evaluate the correlation of baseline genomic alterations with clinical outcome.10 Years
Evaluate the correlation of baseline genomic alterations with clinical outcome.
- Identify biomarkers that predict risk of adverse outcomes that occur following pediatric cancer therapy.10 Years
Identify biomarkers that predict risk of adverse outcomes that occur following pediatric cancer therapy.